Crescita Therapeutics Inc (CTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Crescita Therapeutics Inc (CTX) has a cash flow conversion efficiency ratio of 0.027x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$416.00K ≈ $300.93K USD) by net assets (CA$15.58 Million ≈ $11.27 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Crescita Therapeutics Inc (CTX) total market value for the company's overall valuation and market capitalisation.
Crescita Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Crescita Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Crescita Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Crescita Therapeutics Inc ranked by their cash flow conversion efficiency. Explore how high is Crescita Therapeutics Inc's earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
DevPort AB (publ)
ST:DEVP-B
|
-0.027x |
|
Perfect Moment Ltd.
NYSE MKT:PMNT
|
2.134x |
|
Juggernaut Exploration Ltd
V:JUGR
|
-0.036x |
|
In8bio Inc
NASDAQ:INAB
|
-0.204x |
|
K-Tig Ltd
AU:KTG
|
0.748x |
|
Noviqtech Ltd
AU:NVQ
|
2.158x |
|
Aalborg Boldspilklub A/S
CO:AAB
|
-0.204x |
|
Plurilock Security Inc
V:PLUR
|
0.390x |
Annual Cash Flow Conversion Efficiency for Crescita Therapeutics Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of Crescita Therapeutics Inc from 2014 to 2025. View Crescita Therapeutics Inc (CTX) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CA$15.58 Million ≈ $11.27 Million |
CA$1.07 Million ≈ $776.19K |
0.069x | -59.98% |
| 2024-12-31 | CA$15.83 Million ≈ $11.45 Million |
CA$2.73 Million ≈ $1.97 Million |
0.172x | +56.08% |
| 2023-12-31 | CA$18.82 Million ≈ $13.62 Million |
CA$2.08 Million ≈ $1.50 Million |
0.110x | +328.12% |
| 2022-12-31 | CA$21.10 Million ≈ $15.26 Million |
CA$-1.02 Million ≈ $-737.85K |
-0.048x | +37.86% |
| 2021-12-31 | CA$20.53 Million ≈ $14.85 Million |
CA$-1.60 Million ≈ $-1.16 Million |
-0.078x | -129.32% |
| 2020-12-31 | CA$21.13 Million ≈ $15.29 Million |
CA$5.61 Million ≈ $4.06 Million |
0.265x | +5.57% |
| 2019-12-31 | CA$21.11 Million ≈ $15.27 Million |
CA$5.31 Million ≈ $3.84 Million |
0.251x | +423.27% |
| 2018-12-31 | CA$19.01 Million ≈ $13.75 Million |
CA$-1.48 Million ≈ $-1.07 Million |
-0.078x | +86.23% |
| 2017-12-31 | CA$13.11 Million ≈ $9.48 Million |
CA$-7.40 Million ≈ $-5.35 Million |
-0.565x | +18.50% |
| 2016-12-31 | CA$26.81 Million ≈ $19.39 Million |
CA$-18.58 Million ≈ $-13.44 Million |
-0.693x | -116.76% |
| 2015-12-31 | CA$-3.37 Million ≈ $-2.43 Million |
CA$-13.92 Million ≈ $-10.07 Million |
4.135x | -6.57% |
| 2014-12-31 | CA$-2.10 Million ≈ $-1.52 Million |
CA$-9.30 Million ≈ $-6.73 Million |
4.426x | -- |
About Crescita Therapeutics Inc
Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally. It operates through three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The company owns proprietary drug delivery platforms, which include Multiplexed Molecular Penetration Enhanc… Read more